Close

IRLAB Participates in Pareto Securities' 15th Annual Healthcare Conference

September 13, 2024 1:28 AM EDT

GOTHENBURG, SE / ACCESSWIRE / September 13, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, September 13, 2024 - IRLAB Therapeutics AB (Nasdaq Stockholm:IRLAB A), a company discovering and developing novel treatments for Parkinson's disease, today announced that the company will give a presentation at the event Pareto Securities' 15th Annual Healthcare Conference, in Stockholm on September 19, 2024.

Kristina Torfgård, CEO, will attend and present IRLAB at the event, hosted by Pareto Securities at Downtown Camper Scandic in Stockholm City.

"I am looking forward to meeting current and potential new investors to present our leading portfolio in Parkinson's disease and the progress we are making. These are very exciting times for IRLAB," said Kristina Torfgård, CEO.

More information about the event can be found on Pareto's webpage:
https://paretosec.com/updates/events-and-conferences

For more information

Kristina Torfgård, CEO
Phone: +46 730 60 70 99
E-mail: [email protected]

About IRLAB

IRLAB discovers and develops a portfolio of transformative treatments for all stages of Parkinson's disease. The company originates from Nobel Laureate Prof Arvid Carlsson's research group and the discovery of a link between brain neurotransmitter disorders and brain diseases. Mesdopetam (IRL790), under development for treating levodopa-induced dyskinesias, has completed Phase IIb and is in preparation for Phase III. Pirepemat (IRL752), currently in Phase IIb, is being evaluated for its effect on balance and fall frequency in Parkinson's disease. IRL757, a compound being developed for the treatment of apathy in neurodegenerative disorders, is in Phase I. In addition, the company is developing two preclinical programs, IRL942 and IRL1117, towards Phase I studies. IRLAB's pipeline has been generated by the company's proprietary systems biology-based research platform Integrative Screening Process (ISP). Headquartered in Sweden, IRLAB is listed on Nasdaq Stockholm (IRLAB A). For more information, please visit www.irlab.se .

Attachments

IRLAB participates in Pareto Securities' 15th Annual Healthcare Conference

SOURCE: IRLAB Therapeutics



View the original press release on accesswire.com



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Accesswire, Press Releases

Related Entities

Maynard Um, Mark Zuckerberg, ARK